Potansiyel MAO-B İnhibitörü Olarak Propargil Yan Zinciri İçeren Yeni Bileşiklerin Sentezi ve Karakterizasyonu

Year 2020, , 755 - 763, 30.12.2020

Derya Osmaniye , Yusuf Özkay

https://doi.org/10.35193/bseufbd.681580

Abstract

Bu çalışma kapsamında, propargil grubunun Monoaminoksidaz-B (MAO-B) enzimi üzerindeki potansiyel inhibitör etkinliği dikkate alınarak bazı yeni propargil grubu içeren bileşikler sentezlenmiştir. Sentez çalışmalarında, 2- klorobenzimidazol NaH varlığında propargil bromür ile reaksiyona sokulmuş bileşik 1 elde edilmiştir. Bileşik 1 çeşitli benzilamin türevleri ile potasyum karbonat katalizörlüğünde muamele edilerek sonuç ürünlerine (2a-2c) ulaşılmıştır. Elde edilen bileşiklerin yapıları 1HNMR ve 13C-NMR ve HRMS spektroskopik yöntemleri ile doğrulanmıştır. Sentezlenen bileşiklerin MAO enzimleri üzerindeki etkileri in-vitro şartlarda florimetrik yöntem kullanılarak araştırılmıştır. Yapılan aktivite çalışmaları sonucunda sentezlenen bileşiklerin MAO enzimlerini değişen düzeylerde inhibe ettiği tespit edilmiştir.

Keywords

Propargil, Benzimidazol, NMR, Monoamin Oksidaz, Parkinson Hastalığı

Synthesis and Characterization of New Compounds Including Propargyl Side Chain as Potential MAO-B Inhibitor

Abstract

In this study, some new propargyl derivatives were synthesized considering potential monoamine oxidase-B (MAO-B) inhibition potency of propargyl moiety. In synthesis studies, 2-chlorobenzimidazole was reacted with propargyl bromide in the presence of NaH and compound 1 was obtained. Compound 1 was treated with various benzylamine derivatives and final products (2a-2c) were gained. Structures of obtained compounds were established by spectroscopic methods. Effects of the synthesized compounds against MAO enzymes were observed by using in-vitro fluorimetric method. Activity studies revealed that synthesis compounds inhibited MAO enzymes to different extends. .

Keywords

Propargyl, Benzimidazole, NMR, Monoamine Oxydase, Parkinson’s Disease

References

• Zindo, F. T., Malan, S. F., Omoruyi, S. I., Enogieru, A. B., Ekpo, O. E., Joubert, J. (2019). Design, synthesis and evaluation of pentacycloundecane and hexacycloundecane propargylamine derivatives as multifunctional neuroprotective agents. European journal of medicinal chemistry, 163, 83-94.
• Kumar, B., Kumar, V., Prashar, V., Saini, S., Dwivedi, A. R., Bajaj, B., Mehta, D., Parkash, J., Kumar, V. (2019). Dipropargyl substituted diphenylpyrimidines as dual inhibitors of monoamine oxidase and acetylcholinesterase. European journal of medicinal chemistry, 177, 221-234.
• Sasidharan, R., Baek, S. C., Leelabaiamma, M. S., Kim, H., Mathew, B. (2018). Imidazole bearing chalcones as a new class of monoamine oxidase inhibitors. Biomedicine & Pharmacotherapy, 106, 8-13.
• Szökő, É., Tábi, T., Riederer, P., Vécsei, L., Magyar, K. (2018). Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson’s disease. Journal of Neural Transmission, 125(11), 1735-1749.
• Zhou, S., Chen, G., & Huang, G. (2018). Design, synthesis and biological evaluation of lazabemide derivatives as inhibitors of monoamine oxidase. Bioorganic & medicinal chemistry, 26(17), 4863-4870.
• Finberg, J. P. (2019). Inhibitors of MAO-B and COMT: Their effects on brain dopamine levels and uses in Parkinson’s disease. Journal of Neural Transmission, 126(4), 433-448.
• Kumar, B., Kumar, M., Dwivedi, A. R., Kumar, V. (2018). Synthesis, Biological Evaluation and Molecular Modeling Studies of Propargyl‐Containing 2, 4, 6‐Trisubstituted Pyrimidine Derivatives as Potential Anti‐Parkinson Agents. ChemMedChem, 13(7), 705-712.
• Mathew, B., Parambi, D. G., Mathew, G. E., Uddin, M. S., Inasu, S. T., Kim, H., Marathakam, A., Unnikrishnan, M., Carradori, S. (2019). Emerging therapeutic potentials of dual‐acting MAO and AChE inhibitors in Alzheimer's and Parkinson's diseases. Archiv der Pharmazie, 352(11), 1900177.
• Tripathi, R. K. P., Ayyannan, S. R. (2019). Monoamine oxidase‐B inhibitors as potential neurotherapeutic agents: An overview and update. Medicinal research reviews, 39(5), 1603-1706.
• Cakmur, R. (2011). Parkinson hastalığı ve medikal tedavisi. Klinik Gelişim, 53-58.
• Demirkiran, M., Jankovic, J. (1995). Paroxysmal dyskinesias: clinical features and classification. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society, 38(4), 571-579.
• Uzbay, T. (2007). Nöropsikofarmakoloji: Rasyonel ilaç kullanımı. Medikal Yayıncılık, İstanbul, 110-115.
• Kayaalp, O. (2005). Rasyonel Tedavi Yönünden Tıbbi Farmakoloji. Hacettepe Taş Yayınları, Ankara, 913-918.
• Mancuso, R., Veltri, L., Russo, P., Grasso, G., Cuocci, C., Romeo, R., Gabriele, B. (2018). Palladium-catalyzed carbonylative synthesis of functionalized benzimidazopyrimidinones. Synthesis, 50(02), 267-277.
• Can, Ö. D., Osmaniye, D., Özkay, Ü. D., Sağlık, B. N., Levent, S., Ilgın, S., Baysal, M., Özkay, Y., Kaplancıklı, Z. A. (2017). MAO enzymes inhibitory activity of new benzimidazole derivatives including hydrazone and propargyl side chains. European journal of medicinal chemistry, 131, 92-106.
• Can, N. Ö., Osmaniye, D., Levent, S., Sağlık, B. N., Korkut, B., Atlı, Ö., Özkay, Y., Kaplancıklı, Z. A. (2018). Design, synthesis and biological assessment of new thiazolylhydrazine derivatives as selective and reversible hMAO-A inhibitors. European journal of medicinal chemistry, 144, 68-81.
• Ilgın, S., Osmaniye, D., Levent, S., Sağlık, B. N., Acar Çevik, U., Çavuşoğlu, B. K., Özkay, Y., Kaplancıklı, Z. A. (2017). Design and synthesis of new benzothiazole compounds as selective hMAO-B inhibitors. Molecules, 22(12), 2187.
• Sağlık, B. N., Çavuşoğlu, B. K., Osmaniye, D., Levent, S., Çevik, U. A., Ilgın, S., Özkay, Y., Kaplancıklı, Z.A., Öztürk, Y. (2019). In vitro and in silico evaluation of new thiazole compounds as monoamine oxidase inhibitors. Bioorganic chemistry, 85, 97-108.
• Youdim, M. B., Gross, A., & Finberg, J. P. (2001). Rasagiline [N‐propargyl‐1R (+)‐aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. British journal of pharmacology, 132(2), 500-506.
• Knudsen Gerber, D. (2011). Selegiline and rasagiline: twins or distant cousins? Guidelines. The Consultant Pharmacist®, 26(1), 48-51.
• Chioua, M., González‐Camuñas, A., Catarozzo, M. T., Alcaro, S., Ortuso, F., Yáñez, M., Marco‐Contelles, J. (2019). Synthesis, Monoamine Oxidase Inhibition and Computational Analysis of Diversely Substituted N‐Propargylated‐1, 3, 5‐triazines. ChemistrySelect, 4(28), 8334-8337.
• Knez, D., Colettis, N., Iacovino, L. G., Sova, M., Pislar, A., Konc, J., Lesnik, S., Higgs, J., Kamecki, F., Mangialavori, I., Dolsak, A., Zakelj, S., Tronteli, J., Kos, J., Binda, C., Marder, M., Dolsak, A. (2020). Stereoselective Activity of 1-Propargyl-4-styrylpiperidine-like Analogues That Can Discriminate between Monoamine Oxidase Isoforms A and B. Journal of Medicinal Chemistry, 63(3), 1361-1387.
• Kumar, B., Kumar, M., Dwivedi, A. R., Kumar, V. (2018). Synthesis, Biological Evaluation and Molecular Modeling Studies of Propargyl‐Containing 2, 4, 6‐Trisubstituted Pyrimidine Derivatives as Potential Anti‐Parkinson Agents. ChemMedChem, 13(7), 705-712.
• Nag, S., Kettschau, G., Heinrich, T., Varrone, A., Lehmann, L., Gulyas, B., Thiele, A., Keller, E., Halldin, C. (2013). Synthesis and biological evaluation of novel propargyl amines as potential fluorine-18 labeled radioligands for detection of MAO-B activity. Bioorganic & medicinal chemistry, 21(1), 186-195.